Oxiracetam foda (62613-82-5)

Aniracetam, wanda aka fi sani da Ampamet da Ro-13-5057, mai haɓaka haɓakar haɓaka ce mai nau'in pyrrolidinone wanda aka yi amfani da shi a asibiti don kula da halayyar mutum da halayyar mutum na rashin hankali bayan bugun jini da kuma cutar Alzheimer. Aniracetam ya bayyana da kyau canza masu karɓa na metabotropic glutamate da alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) - masu karɓar glutamate masu mahimmanci, kuma na iya sauƙaƙe watsa kwayar cuta, sakamakon da wataƙila ke da alaƙa da tsarin aikinsa.

Piracetam shine farkon magungunan nootropic da aka taɓa ganowa a cikin shekarun 1960. Anyi amfani dashi da farko don taimakawa mutane masu cutar motsi. Ba da daɗewa ba bayan ganota, an yi nazarin wannan magani don illar da ke cikin ƙwaƙwalwar ajiya a cikin 1971.1

Veryan fari na farko na nootropics mallakar wani rukunin da ake kira racetams. Wannan ya hada da piracetam, wanda shine farkon magungunan nootropic da za'ayi nazari sosai. An gano wannan maganin yana da tasirin gaske a ƙwaƙwalwar ajiya, koyo, fahimta, da yanayi. Ba da daɗewa ba bayan gano piracetam, aniracetam da sauran hanyoyin sun gano kuma sun haɓaka azaman nootropic jamiái.

Dalilin da kwayoyin cutar aniracetam take dashi shine saboda aniracetam ta banbanta da sauran kwayoyi a cikin dangi. Piracetam da aniracetam suna da bambancin magunguna saboda bambance-bambance a cikin aikin su.

Aniracetam yana shiga cikin hanzarin shiga cikin jini kuma yana da ɗan gajeren rayuwar, wanda ya sa ya zama kayan aiki mai mahimmanci don amfani da hankali da fa'idar taro. Yawancin mutane waɗanda ke amfani da aniracetam a kan al'ummomin yanar gizo suna lura cewa kayan aiki ne mai wuce yarda.

Kodayake maganin aniracetam da aka ba da shawarar yana kusa da 750 mg x 2 servings, kuna iya zama mafi alh offri a ɗaukar ƙarin servings fiye da biyu saboda tasirin ƙarfafawa. Kuna iya ɗaukar nauyin 3 - 4 na ƙananan allurai don samun cikakken tasirin.

An rarraba shi azaman ƙwaƙwalwar ƙwayar cuta, aniracetam yawanci ana amfani dashi a cikin madadin magani mafi ƙarancin ƙwaƙwalwar ajiya, inganta taro, da haɓaka faɗakarwa. Bugu da kari, wani lokacin ana amfani da aniracetam don halaye masu zuwa:

Alzheimer ta cutar

rashin kulawar rashin lafiya na rashin lafiya

tashin hankali

ciki

motsi mara nauyi

rashin barci

Aniracetam kuma touted a matsayin anti-tsufa wakili.

Aniracetam memba ne na ajin nootropic na kwayoyi, waɗanda ke da damar haɓaka haɓakawa. Ya bayyana don daidaita ingantattun masu karɓar glutamate metabotropic da alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) -nagane masu haɗarin glutamate, kuma na iya sauƙaƙe watsa cholinergic, tasirin waɗanda maiyuwa suna da alaƙa da tsarin aikinsa. Sakamako daga gwaji a cikin tsofaffi marasa lafiya tare da laushi na matsakaici na matsakaici na nakasa saboda ƙarancin ƙwayar cuta na nau'in Alzheimer yana ba da shawarar cewa aniracetam na iya zama da fa'ida, tare da ƙarin gwaji da ake buƙata don tabbatar da ingancin bayanin martabarsa da kuma ayyana ainihin ainihin waɗannan marasa lafiya da alama su amsa magani . Aniracetam 1500 mg / rana ya fi tasiri sosai fiye da placebo a duk gwaje-gwaje a watanni 4 da 6, kuma a cikin ƙarin gwajin watanni 6 ya fi tasiri fiye da piracetam 2400 mg / rana a cikin 8 na 18 gwaje-gwaje. Bayani na farko a cikin kulawa da marasa lafiya tare da raunin hankali na asalin ƙwayar cuta yana nuna aniracetam na iya kasancewa da fa'ida a cikin wannan yanayin. Duk da cewa har yanzu ba'a samu ƙarancin bala'in sakamako ba, bayanai daga gwaji sun nuna an yarda da aniracetam. Musamman, aniracetam bai bayyana ba don haifar da karuwa a cikin matakan enzyme hanta. Evaluationididdigar magungunan marasa lafiya ga marasa lafiya tare da rikice rikice na tsufa yanki ne mai wahala kuma zaɓuɓɓukan warkewa a halin yanzu sun iyakance. Hujja ta farko game da fa'idar fa'idodi da kyakkyawar juriya na tallafin aniracetam ya ci gaba da kimanta amfani da shi a cikin marassa lafiya da laulayi mai laushi zuwa matsakaici na nau'in Alzheimer.

COA

• Elston TW, Pandian A, Smith GD, Holley AJ, Gao N, Lugo JN. Aniracetam baya canza fahimta da halayyar tasiri a cikin manya C57BL / 6J mice. PLoS Daya. 2014 Aug 6; 9 (8): e104443. doi: 10.1371 / journal.pone.0104443. PubMed PMID: 25099639; PubMed Central PMCID: PMC4123976.
• Koliaki CC, Messini C, Tsolaki M. Sakamakon aikin asibiti na aniracetam, ko dai azaman monotherapy ko haɗa tare da inhibitors na cholinesterase, a cikin marasa lafiya tare da raunin hankali: nazarin buɗewar kamantawa. CNS Neurosci Ther. 2012 Apr; 18 (4): 302-12. doi: 10.1111 / j.1755-5949.2010.00244.x. PubMed PMID: 22070796.
• Li Y, Hu D, Sun Y. determinationarfafawar abun cikin aniracetam a cikin hadaddiyar haɗakar aniracetam ta HPLC. Kwayoyin Artif Kwayoyin Jiki na jini Immobil Biotechnol. 2009; 37 (3): 143-5. doi: 10.1080 / 10731190902908387. PubMed PMID: 19412824.
• Jagorar kwatancen Karshe na Racetam Nootropics
• Jagora na Sunifiram vs Unifiram a cikin 2020: Wanne ne ya fi kyau?
• Aniracetam Review: Shin wannan Nootropic foda yana da kyau a gare ku?
• 2020 Mafi Nootropic Choline Source Citicoline Vs. Alfa GPC
• 2020 Babban Jagora na Sesamol Antioxidant
• Oxiracetam Nootropics: Duk Abin da kuke Bukatar Ku sani game da wannan Nootropic A cikin Iyalin Racetam